A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor ; volume:118 ; number:02 ; year:2018 ; pages:298-308
Thrombosis and haemostasis ; 118, Heft 02 (2018), 298-308
- Contributor
-
Stanne, Tara M.
Olsson, Maja
Lorentzen, Erik
Pedersen, Annie
Gummesson, Anders
Gils, Ann
Jood, Katarina
Engström, Gunnar
Melander, Olle
Declerck, Paul J.
Jern, Christina
- DOI
-
10.1160/TH17-04-0249
- URN
-
urn:nbn:de:101:1-2018110310070104316578
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Stanne, Tara M.
- Olsson, Maja
- Lorentzen, Erik
- Pedersen, Annie
- Gummesson, Anders
- Gils, Ann
- Jood, Katarina
- Engström, Gunnar
- Melander, Olle
- Declerck, Paul J.
- Jern, Christina
Other Objects (12)
Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI)
High thrombin-activatable fibrinolysis inhibitor expression in thrombi from stroke patients in elevated estrogen states
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke
Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis
Untersuchungen zur interindividuellen Variation der Konzentration von Thrombin Activatable Fibrinolysis Inhibitor (TAFI) und seiner Korrelation zu Parametern des Stoffwechsels und der Blutgerinnung
Determination of thrombin activatable fibrinolysis inhibitor (TAFI) activity by liquid chromatography/electrospray ionization mass spectrometry and its potential role in hemophilia : = Bestimmung der Thrombin-aktivierbarer Fibrinolyseinhibitor (TAFI)-Aktivität durch Flüssigkeitschromatographie/Tandem-Massenspektrometrie und die mögliche Rolle bei Hämophilie-Patienten
Impaired fibrinolysis in patients with atrial fibrillation and elevated circulating lipopolysaccharide
Measuring Fibrinolysis
Large-scale preparation of active caspase-3 in E. coli by designing its thrombin-activatable precursors
Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer
Extent of peritoneal metastases from colorectal cancer is not associated with changes in thrombin generation or fibrinolysis
Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI)
High thrombin-activatable fibrinolysis inhibitor expression in thrombi from stroke patients in elevated estrogen states
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke
Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis
Untersuchungen zur interindividuellen Variation der Konzentration von Thrombin Activatable Fibrinolysis Inhibitor (TAFI) und seiner Korrelation zu Parametern des Stoffwechsels und der Blutgerinnung
Determination of thrombin activatable fibrinolysis inhibitor (TAFI) activity by liquid chromatography/electrospray ionization mass spectrometry and its potential role in hemophilia : = Bestimmung der Thrombin-aktivierbarer Fibrinolyseinhibitor (TAFI)-Aktivität durch Flüssigkeitschromatographie/Tandem-Massenspektrometrie und die mögliche Rolle bei Hämophilie-Patienten
Impaired fibrinolysis in patients with atrial fibrillation and elevated circulating lipopolysaccharide
Measuring Fibrinolysis
Large-scale preparation of active caspase-3 in E. coli by designing its thrombin-activatable precursors
Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer
Extent of peritoneal metastases from colorectal cancer is not associated with changes in thrombin generation or fibrinolysis
Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI)
High thrombin-activatable fibrinolysis inhibitor expression in thrombi from stroke patients in elevated estrogen states
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke
Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis
Untersuchungen zur interindividuellen Variation der Konzentration von Thrombin Activatable Fibrinolysis Inhibitor (TAFI) und seiner Korrelation zu Parametern des Stoffwechsels und der Blutgerinnung
Determination of thrombin activatable fibrinolysis inhibitor (TAFI) activity by liquid chromatography/electrospray ionization mass spectrometry and its potential role in hemophilia : = Bestimmung der Thrombin-aktivierbarer Fibrinolyseinhibitor (TAFI)-Aktivität durch Flüssigkeitschromatographie/Tandem-Massenspektrometrie und die mögliche Rolle bei Hämophilie-Patienten
Impaired fibrinolysis in patients with atrial fibrillation and elevated circulating lipopolysaccharide
Measuring Fibrinolysis
Large-scale preparation of active caspase-3 in E. coli by designing its thrombin-activatable precursors
Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer